Bausch & Lomb (TSX:BLCO) Gross-Profit-to-Asset % : 21.40% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Bausch & Lomb's annualized Gross Profit for the quarter that ended in Dec. 2023 was C$3,821 Mil. Bausch & Lomb's average Total Assets over the quarter that ended in Dec. 2023 was C$17,858 Mil. Therefore, Bausch & Lomb's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 21.40%.

Bausch & Lomb Gross-Profit-to-Asset % Historical Data

The historical data trend for Bausch & Lomb's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Gross-Profit-to-Asset % Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

21.37

18.45

20.80

21.08

20.25

Bausch & Lomb Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial											21.29	20.11	21.67	20.35	21.40

Competitive Comparison of Bausch & Lomb's Gross-Profit-to-Asset %

For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bausch & Lomb's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Bausch & Lomb's Gross-Profit-to-Asset % falls into.

Bausch & Lomb Gross-Profit-to-Asset % Calculation

Bausch & Lomb's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	3359.366	/	( (15139.124	+	18033.787)	/ 2 )
	=	3359.366	/	16586.4555
	=	20.25 %

Bausch & Lomb's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	3820.876	/	( (17682.311	+	18033.787)	/ 2 )
	=	3820.876	/	17858.049
	=	21.40 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Bausch & Lomb Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb (TSX:BLCO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

BLCO:USA S2L:Germany

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.